Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic

Eur J Cancer. 2020 Aug;135:147-149. doi: 10.1016/j.ejca.2020.06.004. Epub 2020 Jun 17.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Betacoronavirus / isolation & purification*
  • Clinical Laboratory Techniques / standards
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / virology
  • Delayed Diagnosis
  • Diagnosis, Differential
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Ipilimumab / adverse effects
  • Length of Stay
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / immunology
  • Liver Neoplasms / secondary
  • Lung / diagnostic imaging
  • Male
  • Melanoma / drug therapy
  • Melanoma / immunology
  • Melanoma / secondary
  • Methylprednisolone / therapeutic use
  • Nasopharynx / virology
  • Neoplasms, Unknown Primary / drug therapy
  • Neoplasms, Unknown Primary / immunology
  • Nivolumab / adverse effects
  • Pandemics
  • Pneumonia / diagnosis*
  • Pneumonia / drug therapy
  • Pneumonia / immunology
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / virology
  • Time Factors
  • Time-to-Treatment
  • Tomography, X-Ray Computed
  • Uveal Neoplasms / drug therapy
  • Uveal Neoplasms / immunology
  • Uveal Neoplasms / secondary

Substances

  • Glucocorticoids
  • Ipilimumab
  • Nivolumab
  • Methylprednisolone

Supplementary concepts

  • COVID-19
  • COVID-19 diagnostic testing
  • Uveal melanoma
  • severe acute respiratory syndrome coronavirus 2